Healio: Glecaprevir/pibrentasvir highly effective for treating HCV genotype 1
January 25, 2017
Glecaprevir/pibrentasvir was highly effective and well tolerated for the treatment of hepatitis C virus genotype 1 infection in patients who previously failed treatment with direct-acting antivirals, according to the results of the phase 2 open-label MAGELLAN-1 study. Read the full story at Healio
